Print Page | Sign In
Marc Epstein, DO, FAOCD
Share |

After graduating from the Philadelphia College of Osteopathic Medicine in 1981, Dr. Epstein completed residencies in internal medicine at Delaware Valley Medical Center, Langhorne, PA and in dermatology at Temple University, Skin and Cancer Center, Philadelphia, PA. He then served in the USAF for nine years active duty as Chief of Dermatology Services at Davis-Monthan Air Force Base in Tucson, AZ, followed by 16 years of reserve duty, obtaining the rank of colonel. Upon leaving active military duty in 1995, Dr. Epstein opened his private dermatology practice in Tucson AZ, where his dermatology skills have been serving the community’s needs for over 20 years.

Dr. Epstein received his board certification in dermatology from the American Osteopathic Board of Dermatology (AOBD) to become a Fellow of the AOCD and then achieved Distinguished Fellow Status. He served on the board of the AOCD as vice president and then President. His professional credentials include former Clinical Instructor of Dermatology at the University of Arizona, former Principal Dermatology Investigator for Argus, Hilltop and then Radiant Research and former dermatology section chief at Tucson Medical Center. His medical community memberships include the Tucson Dermatology Society, where he served as its president for over 6 years, the American Academy of Dermatology, the Arizona Dermatology Society, the Southwestern Dermatology Society and the American Society for Laser Medicine and Surgery. 

Medical Marijuana and Dermatology

What is medical marijuana? Where medical marijuana is legal and what ailments a physician is allowed to treat. The history of medical marijuana.


  1. Medical marijuana when used legally and appropriately is a safe and effective treatment modality
  2. Medical marijuana does not meet the criteria to be classified as a Schedule 1 Drug
  3. Topically applied medical marijuana (THC) can effectively attenuate the inflammation and pruritus of contact allergic dermatitis by decreasing keratinocyte derived pro-inflammatory mediators


  1. New advances in dermatologic treatment
  2. Availability of new medication(s) and indication(s)
  3. Development of new technology
  4. Advances in medical knowledge
  5. Legislative, regulatory, or organizational changes effecting patient care


  1. “Cannabis: Collected Clinical Papers” vol. 1, Marijuana: Medical Papers. 1839-1972. Ed. Tod. H. Mikuriya, MD.
  2. Olah, A et al. “Cannabidiol Sebostatic & Anti-inflammatory effects” J Clin Invest. 2014, 11(9), 3713-24.
  3. Biro, T. et al. “The Endocannabinoid System & The Skin in Health & Disease”. Trends in Pharmacol. Sci., 2009.

Core competencies: 2, 3, 6

Disclosures: Off-label: Medical marijuana is state approved (including CA where lecture is being given and 24 other states) but is not yet federally approved.

2902 North Baltimore Street | P.O. Box 7525 | Kirksville, Missouri 63501

660-665-2184 | 1-800-449-2623 | 660-627-2623

General Terms of Use Policy
The AOCD web site and AOCD apps contain copyrighted material and other proprietary information, which may include, but is not limited to: text, software, photos, video, graphics and audio. It is not permitted to modify, publish, transmit, participate in the transfer or sale, create derivative works, or in any way exploit any of the content, in whole or in part.

The AOCD limits permission for downloading education material for personal use only.